Get the Stockscreener App
8.35
1.21%
0.10
Xilio Therapeutics Inc stock is traded at $8.35, with a volume of 22,654.
It is up +1.21% in the last 24 hours and up +0.48% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
See More
Previous Close:
$8.25
Open:
$8.41
24h Volume:
22,654
Relative Volume:
0.48
Market Cap:
$49.96M
Revenue:
$43.77M
Net Income/Loss:
$-35.04M
P/E Ratio:
-2.5676
EPS:
-3.2521
Net Cash Flow:
$-5.51M
1W Performance:
+2.08%
1M Performance:
+0.48%
6M Performance:
-20.49%
1Y Performance:
-32.52%
1-Day Range:
$8.285
$8.5599
1-Week Range:
$7.97
$8.6659
52-Week Range:
$6.4652
$16.10
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
8.35 | 49.36M | 43.77M | -35.04M | -5.51M | -3.2521 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
XLO Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesCommunity Buy Signals - Newser
Is Xilio Therapeutics (XLO) Still a Buy After +2.89% Rally? 2026-05-21Wyckoff Upthrust - Newser
Xilio Therapeutics (XLO) Crushes Q1 2026 Estimates — EPS $-0.58 Tops ViewsHigh Interest Stocks - Newser
Cancer Stocks That Are Advancing the Future of Oncology Care - TradingView
Xilio Therapeutics, Inc. (XLO) reports Q1 loss, beats revenue estimates - MSN
Xilio Therapeutics (XLO) Stock Analysis: Falls -5.11%, Watching $7.94 2026-05-17Technical Analysis - Newser
Xilio Therapeutics (XLO) upgraded to buy: What does it mean for the stock? - MSN
OrbiMed group discloses stakes in Xilio Therapeutics (NASDAQ: XLO), up to 9.99% - Stock Titan
Bain Capital entities report 9.99% stake in Xilio Therapeutics (XLO) - Stock Titan
Point72 (XLO) files 13G/A showing 0% stake in Xilio Therapeutics - Stock Titan
Sirenia and Alex Silverstein report 9.9% stake in Xilio (NASDAQ: XLO) - Stock Titan
TradingKey - TradingKey
Xilio Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Xilio Therapeutics, Inc. 2026 Q1 Quarterly Report: Financials, Risk Factors, and Business Overview - Minichart
XLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sagimet Biosciences Releases Q1 2026 Financial Results - AlphaStreet
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Xilio Therapeutics Reports Q1 2026 Financial Results, Advances Pipeline with XTX501 IND Filing and AbbVie Milestone Extension - Minichart
Xilio Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
According to documents submitted to the U.S. Securities and Exchange Commission (SEC), biotechnology company Xilio Therapeutics Inc. has entered into a common stock sales agreement with investment bank Leerink Partners LLC. - Bitget
Xilio Therapeutics (NASDAQ: XLO) files $250M shelf, includes $17.22M ATM - Stock Titan
Xilio Therapeutics, Inc. 1Q 2026: Revenue $12.6M, EPS $(0.58) — 10-Q Summary - TradingView
Xilio Therapeutics (XLO) boosts Q1 2026 collaboration revenue and extends cash runway into 2028 - Stock Titan
Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Xilio (Nasdaq: XLO) Q1 2026 loss narrows as cash runway extends to 2028 - Stock Titan
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and ... - Caledonian Record
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates - GlobeNewswire
XLO (Xilio Therapeutics) swings to profit, crushing estimates by 147.7 percent as stock gains.Expert Momentum Signals - newser.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2026 - marketscreener.com
Number of shareholders of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
XLO Xilio Therapeutics smashes Q4 earnings with 147.7% beat, 589.9% revenue surge, yet shares fall 1.14%.Expert Entry Points - newser.com
Xilio Therapeutics Grants Options for 146,800 Shares to New Employees - geneonline.com
New Xilio hire gets stock options for 1,982 shares at $8.32 - Stock Titan
Actuate Therapeutics Adds Oncology Expert to Board Leadership - TipRanks
Actuate Therapeutics appoints Martin Huber to board By Investing.com - Investing.com Australia
Xilio Therapeutics Inc expected to post a loss of 66 cents a shareEarnings Preview - TradingView
Net current asset value per share of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
XLO Q1'26 Earnings: revenue estimate is 8.52M USD - TradingView
Xilio Therapeutics (XLO) price target decreased by 28.57% to 20.40 - MSN
[ARS] Xilio Therapeutics, Inc. SEC Filing - Stock Titan
Xilio Therapeutics | ARS: Annual Report to Security Holders - Moomoo
Stock plan change and virtual 2026 annual meeting at Xilio (XLO) - Stock Titan
What failed trades Xilio Therapeutics (XLO)? (Slight Gain) 2026-04-27Market Expert Watchlist - Newser
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split - WFXG
Xilio Therapeutics | 8-K: Current report - Moomoo
Xilio Therapeutics (XLO) Stock: Growth Outlook (+2.63%) 2026-04-18Sector Analysis - Xã Vĩnh Công
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 - Sahm
XLO: Xilio Therapeutics Presents Promising Preclinical Findings for XTX601 at AACR - GuruFocus
Xilio announces new preclinical data for XTX601 at AACR - TipRanks
Xilio Therapeutics appoints Cheryl Blanchard to board By Investing.com - Investing.com India
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):